Back to top
more

Protalix BioTherapeutics (PLX)

(Real Time Quote from BATS)

$1.14 USD

1.14
50,805

-0.02 (-1.72%)

Updated Jul 29, 2024 11:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Protalix BioTherapeutics, Inc. [PLX]

Reports for Purchase

Showing records 61 - 77 ( 77 total )

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

08/17/2011

Company Report

Pages: 5

PDUFA DATE FOR TALIGLUCERASE ANNOUNCED,MAINTAIN HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

08/09/2011

Company Report

Pages: 5

Protalix submitted responses to CRL, maintain HOLD.

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

05/10/2011

Company Report

Pages: 5

FDA meeting took place, response to CRL expected soon, maintain HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

02/28/2011

Company Report

Pages: 6

DOWNGRADE to HOLD and Remove PT

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

01/02/2011

Industry Report

Pages: 5

CHANGES rATINGS SYSTEM.

Provider: CAPSTONE INVESTMENTS

Analyst: SINE B

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

01/02/2011

Industry Report

Pages: 5

INVESTMENTS CHANGES RATINGS SYSTEM

Provider: CAPSTONE INVESTMENTS

Analyst: SINE B

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

10/12/2010

Industry Report

Pages: 9

KEY TAKEAWAYS FROM DISCUSSION ON M&A TRENDS IN PHARMACEUTICALS-BIOTECH INDUSTRY.

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

09/28/2010

Industry Report

Pages: 5

M&A TRENDS IN BIOTECH AND SPECIALTY PHARMA

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

08/23/2010

Daily Note

Pages: 32

BEST IDEAS

Provider: CAPSTONE INVESTMENTS

Price: 75.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

08/09/2010

Company Report

Pages: 4

Q2 RESULTS SLIGHTLY MISSED CONSENSUS ; FUNDAMENTAL STORY HAS NOT CHANGED.

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

07/12/2010

Company Report

Pages: 4

THE COMPANY''S NEW DRUG APPLICATION (NDA) FOR TALIGLUCERASE ALFA HAS BEEN ACCEPTED FOR REVIEW BY THE FDA

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

06/10/2010

Industry Report

Pages: 5

Healthcare Conference Call

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

06/08/2010

Company Report

Pages: 4

Announced today the positive results

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

05/17/2010

Company Report

Pages: 19

BIOPHARMA COMPANY WITH BREAKTHROUH TECHNOLOGY, FIRST DRUG PENDING FDA APPROVAL. INITIATING WITH BUY RECOMMENDATION.

Provider: CAPSTONE INVESTMENTS

Price: 50.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

05/11/2010

Company Report

Pages: 9

The company is on track for potential FDA review and approval of UPLYSO by Q4:10. Reiterating our BUY rating and $11.50 price target

Provider: SINGULAR RESEARCH

Analyst: DILORENZO F

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

04/27/2010

Company Report

Pages: 8

Expect an FDA decision in the fourth quarter. Reiterating Buy rating and $11.50 price target.

Provider: SINGULAR RESEARCH

Analyst: DILORENZO F

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

03/29/2010

Company Report

Pages: 15

Offers an opportunity in a biotech manufacturing technology that may have solid commercial viability in the biosimilar space. Initiating with a BUY rating and $11.50 price target.

Provider: SINGULAR RESEARCH

Analyst: DILORENZO F

Price: 50.00

Research Provided by a Third Party
// eof